Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4563826, 9 pages
https://doi.org/10.1155/2017/4563826
Research Article

Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China

1Tuberculosis Reference Laboratory, Chongqing Tuberculosis Control Institute, Chongqing 400050, China
2Department of Pathogenic Organisms, Chongqing Medical University, Chongqing 400016, China
3Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, China
4National Tuberculosis Reference Laboratory, National Center for TB Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
5Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China

Correspondence should be addressed to C. Yang; moc.361@minuhcgnay

Received 26 February 2017; Revised 28 May 2017; Accepted 18 June 2017; Published 17 July 2017

Academic Editor: Isabel Portugal

Copyright © 2017 Y. Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization (WHO), “Global Tuberculosis Report. 2016,” http://www.who.int/tb/publications/global_report/en/.
  2. WHO, Global Tuberculosis Control—Surveillance, Planning, Financing, WHO, Geneva, Switzerland, 2010.
  3. Centers for Disease Control and Prevention (CDC), “mergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000–2004,” Morbidity and Mortality Weekly Report, vol. 55, no. 11, pp. 301–305, 2006. View at Google Scholar
  4. World Health Organization, “International Union Against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world,” Tech. Rep. 3, World Health Organization, Geneva, Switzerland.
  5. Y. Zhao, S. Xu, L. Wang et al., “National survey of drug-resistant tuberculosis in China,” New England Journal of Medicine, vol. 366, no. 23, pp. 2161–2170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Dheda, T. Gumbo, N. R. Gandhi et al., “Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis,” The Lancet Respiratory Medicine, vol. 2, no. 4, pp. 321–338, 2014. View at Publisher · View at Google Scholar
  7. M. Yu, M. Wu, and R. Jou, “Extensively drug-resistant tuberculosis, Taiwan,” Emerging Infectious Diseases, vol. 14, no. 5, pp. 849-850, 2008. View at Publisher · View at Google Scholar
  8. E. M. Streicher, B. Müller, V. Chihota et al., “Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa,” Infection, Genetics and Evolution, vol. 12, no. 4, pp. 686–694, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. C. Becerra, S. C. Appleton, M. F. Franke et al., “Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study,” The Lancet, vol. 377, no. 9760, pp. 147–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. World Health Organization, Anti-Tuberculosis Drug Resistance in the World, World Health Organization, Geneva, Switzerland.
  11. Y. Pang, Y. Zhou, B. Zhao et al., “Spoligotyping and drug resistance analysis of Mycobacterium Tuberculosis strains from national survey in China,” PLoS ONE, vol. 7, no. 3, Article ID e32976, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. L. I. Zhao, Q. Sun, H. C. Liu et al., “Analysis of embCAB mutations associated with ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis isolates from China,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 4, pp. 2045–2050, 2015. View at Publisher · View at Google Scholar
  13. Z. Zhang, J. Lu, Y. Wang, Y. Pang, and Y. Zhao, “Prevalence and molecular characterization of fluoroquinolone- Resistant mycobacterium tuberculosis isolates in China,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 1, pp. 364–369, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. “Developing and Strengthening the Global Supply Chain for SLDs for Multidrug-Resistant Tuberculosis: Workshop Summary,” Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation, National Academies Press, Washington , DC, USA, 2013.
  15. Y. Feng, S. Liu, Q. Wang et al., “Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis,” PLoS ONE, vol. 8, no. 2, Article ID e55292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Chen, Z. Yuan, X. Shen, J. Wu, Z. Wu, and B. Xu, “Resistance to second-line antituberculosis drugs and delay in drug susceptibility testing among multidrug-resistant tuberculosis patients in Shanghai,” BioMed Research International, vol. 2016, Article ID 2628913, 8 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. C. N. Paramasivan, F. Rehman, F. Wares et al., “First- and second-line drug resistance patterns among previously treated tuberculosis patients in India,” International Journal of Tuberculosis and Lung Disease, vol. 14, no. 2, pp. 243–246, 2010. View at Google Scholar · View at Scopus
  18. S. E. Smith, J. Ershova, N. Vlasova et al., “Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005–2010,” Emerging Infectious Diseases, vol. 21, no. 6, pp. 1002–1011, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Bakuła, A. Napiórkowska, M. Kamiński et al., “Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates,” Journal of Microbiology, Immunology and Infection, vol. 49, no. 3, pp. 439–444, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Dalton, P. Cegielski, S. Akksilp et al., “Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study,” The Lancet, vol. 380, no. 9851, pp. 1406–1417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Hu, B. Mathema, Q. Zhao et al., “Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China,” Clinical Microbiology and Infection, vol. 21, no. 12, pp. 1093.e9–1093.e18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. A. D. Calver, A. A. Falmer, M. Murray et al., “Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa,” Emerging Infectious Diseases, vol. 16, no. 2, pp. 264–271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Li, Y. Zhang, X. Shen et al., “Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China,” Journal of Infectious Diseases, vol. 195, no. 6, pp. 864–869, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. Q. Yin, W. Jiao, Q. Li et al., “Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012,” BMC Microbiology, vol. 16, no. 1, article 85, 2016. View at Publisher · View at Google Scholar
  25. A. Faustini, A. J. Hall, and C. A. Perucci, “Risk factors for multidrug resistant tuberculosis in Europe: a systematic review,” Thorax, vol. 61, no. 2, pp. 158–163, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. S. Ginsburg, J. H. Grosset, and W. R. Bishai, “Fluoroquinolones, tuberculosis, and resistance,” Lancet Infectious Diseases, vol. 3, no. 7, pp. 432–442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Piton, S. Petrella, M. Delarue et al., “Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase,” PLoS ONE, vol. 5, no. 8, Article ID e12245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Cui, J. Wang, J. Lu, X. Huang, and Z. Hu, “Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009,” BMC Infectious Diseases, vol. 11, article 78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Yuan, T. Zhang, K. Kawakami et al., “Molecular characterization of multidrug- and extensively drug-resistant mycobacterium tuberculosis strains in Jiangxi, China,” Journal of Clinical Microbiology, vol. 50, no. 7, pp. 2404–2413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. T. S. Oh, Y. J. Kim, H. Y. Kang, C. Kim, S. Y. Cho, and H. J. Lee, “RNA expression analysis of efflux pump genes in clinical isolates of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in South Korea,” Infection, Genetics and Evolution, vol. 49, pp. 111–115, 2017. View at Publisher · View at Google Scholar
  31. A. Kanji, R. Hasan, A. Zaver et al., “Alternate efflux pump mechanism may contribute to drug resistance in extensively drug-resistant isolates of Mycobacterium tuberculosis,” International Journal of Mycobacteriology, vol. 5, supplement 1, pp. S97–S98, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Suzuki, C. Katsukawa, A. Tamaru et al., “Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene,” Journal of Clinical Microbiology, vol. 36, no. 5, pp. 1220–1225, 1998. View at Google Scholar · View at Scopus
  33. C. E. Maus, B. B. Plikaytis, and T. M. Shinnick, “Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 8, pp. 3192–3197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. A. Zaunbrecher, R. D. Sikes Jr., B. Metchock, T. M. Shinnick, and J. E. Posey, “Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 47, pp. 20004–20009, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Maruri, T. R. Sterling, A. W. Kaiga et al., “A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 4, pp. 819–831, 2012. View at Publisher · View at Google Scholar · View at Scopus